Amylyx Pharmaceuticals 대차대조표 건전성
재무 건전성 기준 점검 6/6
Amylyx Pharmaceuticals 의 총 주주 지분은 $239.2M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $264.6M 및 $25.4M 입니다.
핵심 정보
0%
부채/자본 비율
US$0
부채
| 이자보상배율 | n/a |
| 현금 | US$250.76m |
| 자본 | US$239.17m |
| 총부채 | US$25.40m |
| 총자산 | US$264.56m |
최근 재무 건전성 업데이트
분석 기사 • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...분석 기사 • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Recent updates
Seeking Alpha • Aug 07
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild
Summary Amylyx Pharmaceuticals (AMLX) is transitioning from its ALS legacy to a late-stage endocrine company, with avexitide as its lead asset. AMLX's $250.8M cash runway extends into 2028, supporting LUCIDITY Phase 3 readout, regulatory submission, and potential 2027 launch without near-term financing risk. LUCIDITY's pivotal trial targets post-bariatric hypoglycemia, a large orphan market with no approved therapies; topline results expected late August or early September 2026. Avexitide's competitive lead, regulatory designations, and a long-acting follow-on candidate position AMLX for first-mover advantage and franchise expansion if LUCIDITY succeeds. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 06
AMLX: Q3 LUCIDITY Outcome Will Shape View On Undervalued Opportunity
Amylyx Pharmaceuticals' updated analyst price target of $25.56, up from $24.40, reflects analysts' focus on the upcoming Phase 3 LUCIDITY readout for avexitide in post bariatric hypoglycemia and the related sales potential cited in recent research. Analyst Commentary Recent research on Amylyx Pharmaceuticals centers on the Phase 3 LUCIDITY study of avexitide in post bariatric hypoglycemia, with several firms updating their price targets and framing both upside potential and execution risks around this single pivotal catalyst.내러티브 업데이트 • Jul 10
AMLX: Phase 3 LUCIDITY Readout Will Drive View On Undervalued Potential
The analyst fair value estimate for Amylyx Pharmaceuticals has been adjusted from $22.20 to $24.40 as analysts reference higher Street price targets, including Guggenheim's move to $40 and the stock's inclusion as a "Best Idea." This is supported by expectations around the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia and the potential of the $6b+ US PBH market. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals focuses heavily on the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia, with valuation views closely tied to how analysts frame the opportunity in the US PBH market and the stock's execution risks around this catalyst.
내러티브 업데이트 • Jun 26
AMLX: Upcoming PBH Phase 3 Readout Will Drive Bullish Repricing
Amylyx Pharmaceuticals' updated analyst price target has shifted from about $32.63 to roughly $37.58, with analysts citing the stock's inclusion on select "Best Idea" lists and expectations around upcoming LUCIDITY trial results as key reasons for the change. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals highlights a cluster of upbeat views ahead of the LUCIDITY Phase 3 readout for avexitide in post-bariatric hypoglycemia.새로운 내러티브 • Apr 02
Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Mar 19
Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Mar 05
PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?분석 기사 • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...분석 기사 • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Apr 03
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...Seeking Alpha • Feb 24
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking Alpha분석 기사 • Dec 19
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...분석 기사 • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Nov 25
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking Alpha분석 기사 • Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...분석 기사 • Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...Seeking Alpha • Jun 25
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025. The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court. Read the full article on Seeking Alpha분석 기사 • Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop
Unfortunately for some shareholders, the Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has dived 31% in the...재무 상태 분석
단기부채: AMLX 의 단기 자산 ( $256.3M )이 단기 부채( $20.1M ).
장기 부채: AMLX의 단기 자산($256.3M)이 장기 부채($5.3M)를 초과합니다.
부채/자본 비율 추이 및 분석
부채 수준: AMLX 부채가 없습니다.
부채 감소: AMLX는 5년 전 부채 대비 자본 비율이 0.8%였으나 현재 부채가 없습니다.
대차대조표
현금 보유 기간 분석
과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.
안정적인 현금 활주로: AMLX 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.
예측 현금 활주로: AMLX 14.6 2.9 14.6 % 매년.
건전한 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/07 18:46 |
| 종가 | 2026/08/07 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Amylyx Pharmaceuticals, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |